Last ¥1,393 JPY
Change Today +6.00 / 0.43%
Volume 792.0K
4151 On Other Exchanges
Symbol
Exchange
Munich
Tokyo
OTC US
As of 2:00 AM 07/9/14 All times are local (Market data is delayed by at least 15 minutes).

kyowa hakko kirin co ltd (4151) Snapshot

Open
¥1,382
Previous Close
¥1,387
Day High
¥1,398
Day Low
¥1,378
52 Week High
06/26/14 - ¥1,412
52 Week Low
07/31/13 - ¥976.00
Market Cap
803.0B
Average Volume 10 Days
839.3K
EPS TTM
¥47.35
Shares Outstanding
576.5M
EX-Date
12/26/14
P/E TM
29.4x
Dividend
¥25.00
Dividend Yield
1.79%
Current Stock Chart for KYOWA HAKKO KIRIN CO LTD (4151)

Related News

No related news articles were found.

kyowa hakko kirin co ltd (4151) Related Businessweek News

No Related Businessweek News Found

kyowa hakko kirin co ltd (4151) Details

Kyowa Hakko Kirin Co., Ltd. manufactures and markets pharmaceuticals and bio-chemicals primarily in Asia, Europe, and the United States. The company’s Pharmaceuticals segment researches, develops, produces, and sells ethical drugs for the treatment of various diseases, including renal anemia, oncology, allergies, and hypertension. Its principal ethical drugs include NESP/ESPO, an ESA formulation; REGPARA, a secondary hyperparathyroidism; CONIEL, a hypertension and angina pectoris; ONGLYZA, a treatment for type 2 diabetes; GRAN, a G-CSF agent; Fentos, a transdermal product; POTELIGEO, an adult T-cell leukemia-lymphoma; Romiplate, a chronic idiopathic thrombocytopenic purpur; ALLELOCK, an antiallergic agent; Patanol antiallergic eye drops; ASACOL, an ulcerative colitis treatment; NOURIAST, an antiparkinsonian agent; and DEPAKENE, an antiepileptic agent. This segment also offers in vitro diagnostic reagents, such as POTELIGEO tests and Determiner clinical chemistry diagnostic reagents. The company’s Bio-chemicals segment produces and sells amino acids, nucleotides, and related compounds for use in pharmaceuticals and their intermediates, health foods, dietary supplements, and cosmetics. This segment also produces plant growth regulators; designs and installs plant facilities and equipment; manufactures active pharmaceutical ingredients, pharmaceutical intermediates, industrial raw materials, and health care products; sale of fine chemicals; and is involved in mail-order sale of healthcare products in Japan. In addition, the company is engaged in pharmaceuticals licensing, as well as insurance, wholesale, and retail activities. The company was founded in 1949 and is headquartered in Tokyo, Japan. Kyowa Hakko Kirin Co., Ltd. is a subsidiary of Kirin Holdings Company, Limited.

7,152 Employees
Last Reported Date: 03/14/14
Founded in 1949

kyowa hakko kirin co ltd (4151) Top Compensated Officers

No compensation data is available at this time for the top officers at this company.

Executives, Board Directors

kyowa hakko kirin co ltd (4151) Key Developments

Kyowa Hakko Kirin Co., Ltd. Announces Future Development Direction for Bardoxolone Methyl (RTA 402)

Kyowa Hakko Kirin Co., Ltd. announced that the company has decided the future development direction in Japan for bardoxolone methyl (RTA 402), a small-molecule compound licensed from Reata Pharmaceuticals Inc. Under the new direction, Kyowa Hakko Kirin will start a new Phase 2 clinical study on bardoxolone methyl. An increased risk was observed in the Phase 3 placebo-controlled comparative clinical study in chronic kidney disease (CKD) patients with type 2 diabetes conducted by Reata in the US, Europe, Canada, Australia, and Central America (the BEACON study), particularly heart failure, in patients in the bardoxolone methyl arm of the study. Therefore, in November 2013 Kyowa Hakko Kirin decided to discontinue a suspended Phase 2 clinical study and to investigate a future development strategy for bardoxolone methyl. Kyowa Hakko Kirin has since decided to continue developing this compound for CKD patients with type 2 diabetes with a particular emphasis on patient safety, following a detailed analysis of the BEACON study data and consultations with the Pharmaceuticals and Medical Devices Agency (PMDA). The company plans to evaluate both the safety and efficacy of bardoxolone methyl in a new Phase 2 clinical study to be performed in Japan.

Kyowa Hakko Kirin Co., Ltd., Q1 2014 Earnings Call, Apr 24, 2014

Kyowa Hakko Kirin Co., Ltd., Q1 2014 Earnings Call, Apr 24, 2014

Kyowa Hakko Kirin Co., Ltd. Reports Consolidated Earnings Results for the First Quarter Ended March 31, 2014; Provides Consolidated Earnings Guidance for the Six Months Ending June 2014; Reaffirms Consolidated Earnings Guidance for the Year Ending December 31, 2014

Kyowa Hakko Kirin Co., Ltd. reported consolidated earnings results for the first quarter ended March 31, 2014. Net sales were ¥86.0 billion against ¥86.6 billion last year. Operating income (prior to amortization of goodwill) was ¥14.7 billion against ¥16.7 billion last year. Operating income was ¥12.4 billion against ¥14.4 billion last year. Ordinary income was ¥12.0 billion against ¥14.8 billion last year. Income before income taxes and minority interests was ¥12.3 billion against ¥18.6 billion last year. Net income was ¥6.3 billion against ¥10.4 billion last year. EPS prior to amortization of goodwill was ¥15.80 against ¥23.39 per share last year. Capital expenditure was ¥5.3 billion against ¥5.3 billion last year. Fully diluted net income per share was ¥11.56 against ¥19.15 last year. For the six months ending June 2014, on consolidated basis, the company expects net sales of ¥163.0 billion, operating income (prior to amortization of goodwill) of ¥20.6 billion and operating income of ¥16.0 billion. Capital expenditure is expected to be ¥15.2 billion, depreciation and amortization expense is expected to be ¥10.8 billion and amortization of intangible fixed assets is expected to be ¥3.7 billion. The company reaffirmed consolidated earnings guidance for the year ending December 31, 2014. The company expects net sales of ¥337.0 billion, operating income (prior to amortization of goodwill) of ¥50.2 billion, operating income of ¥41.0 billion, ordinary income of ¥35.0 billion, income before income taxes and minority interests of ¥34.5 billion and net income of ¥20.0 billion or ¥53.45 per share prior to amortization of goodwill. Capital expenditure is expected to be ¥30.0 billion, depreciation and amortization expense is expected to be ¥22.7 billion and amortization of intangible fixed assets is expected to be ¥7.5 billion. Net income per share is expected to be ¥36.54.

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
4151:JP ¥1,393.00 JPY +6.00

4151 Competitors

Market data is delayed at least 15 minutes.

Company Last Change
Albemarle Corp $72.08 USD -0.18
Nabaltec AG €11.18 EUR 0.00
View Industry Companies
 

Industry Analysis

4151

Industry Average

Valuation 4151 Industry Range
Price/Earnings 29.9x
Price/Sales 2.3x
Price/Book 1.3x
Price/Cash Flow 18.0x
TEV/Sales 2.3x
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact KYOWA HAKKO KIRIN CO LTD, please visit www.kyowa-kirin.co.jp. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.